SQZ Biotechnologies Co. (SQZ): Price and Financial Metrics

SQZ Biotechnologies Co. (SQZ): $1.55

-0.23 (-12.92%)

POWR Rating

Component Grades













Add SQZ to Watchlist
Sign Up

Industry: Biotech



in industry


  • SQZ scores best on the Value dimension, with a Value rank ahead of 69.99% of US stocks.
  • SQZ's strongest trending metric is Quality; it's been moving down over the last 151 days.
  • SQZ ranks lowest in Momentum; there it ranks in the 3rd percentile.

SQZ Stock Summary

  • SQZ has a higher market value than only 17.09% of US stocks; more precisely, its current market capitalization is $78,044,132.
  • SQZ BIOTECHNOLOGIES CO's stock had its IPO on October 30, 2020, making it an older stock than merely 10.27% of US equities in our set.
  • Of note is the ratio of SQZ BIOTECHNOLOGIES CO's sales and general administrative expense to its total operating expenses; just 12.44% of US stocks have a lower such ratio.
  • If you're looking for stocks that are quantitatively similar to SQZ BIOTECHNOLOGIES CO, a group of peers worth examining would be IKNA, SGTX, SLDB, EIGR, and GSIT.
  • Visit SQZ's SEC page to see the company's official filings. To visit the company's web site, go to www.sqzbiotech.com.

SQZ Valuation Summary

  • In comparison to the median Healthcare stock, SQZ's EV/EBIT ratio is 108.14% lower, now standing at -0.7.
  • SQZ's EV/EBIT ratio has moved up 5.4 over the prior 25 months.

Below are key valuation metrics over time for SQZ.

Stock Date P/S P/B P/E EV/EBIT
SQZ 2022-11-25 3.6 1.1 -1 -0.7
SQZ 2022-11-23 3.5 1.1 -1 -0.7
SQZ 2022-11-22 3.4 1.1 -1 -0.7
SQZ 2022-11-21 3.4 1.1 -1 -0.7
SQZ 2022-11-18 3.6 1.2 -1 -0.7
SQZ 2022-11-17 3.6 1.1 -1 -0.7

SQZ's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SQZ has a Quality Grade of C, ranking ahead of 53% of graded US stocks.
  • SQZ's asset turnover comes in at 0.082 -- ranking 279th of 680 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows SQZ's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.082 1 -1.099

SQZ Price Target

For more insight on analysts targets of SQZ, see our SQZ price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $37.67 Average Broker Recommendation 1.2 (Strong Buy)

SQZ Stock Price Chart Interactive Chart >

Price chart for SQZ

SQZ Price/Volume Stats

Current price $1.55 52-week high $12.12
Prev. close $1.78 52-week low $1.48
Day low $1.48 Volume 246,600
Day high $1.72 Avg. volume 198,419
50-day MA $2.67 Dividend yield N/A
200-day MA $3.40 Market Cap 45.65M

SQZ Biotechnologies Co. (SQZ) Company Bio

SQZ Biotechnologies Co. is a clinical-stage biotechnology company, which engages in developing cell therapies for patients with cancer, infectious diseases, and other serious conditions. It operates through SQZ Cell Therapy Platform, which uses membrane disruption to deliver material into cells. The company was founded by Robert S. Langer Jr., Klavis F. Jensen, Agustin Lopez Marquez, and Armon Sharei in March 2013 and is headquartered in Watertown, MA.

SQZ Latest News Stream

Event/Time News Detail
Loading, please wait...

SQZ Latest Social Stream

Loading social stream, please wait...

View Full SQZ Social Stream

Latest SQZ News From Around the Web

Below are the latest news stories about SQZ BIOTECHNOLOGIES CO that investors may wish to consider to help them evaluate SQZ as an investment opportunity.

SQZ Biotechnologies Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

SQZ Biotechnologies ( NYSE:SQZ ) Third Quarter 2022 Results Key Financial Results Revenue: US$3.45m (down 27% from 3Q...

Yahoo | November 12, 2022

SQZ Biotechnologies Presents Cell Squeeze® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual Meeting

WATERTOWN, Mass., November 10, 2022--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, will present preclinical research demonstrating the potential of its Cell Squeeze® technology to multiplex engineer a diverse set of cell types, including hematopoietic stem cells (HSCs) and induced pluripotent stem cells (iPSCs), to potentially support the creation of new therapeutic candidates. This capability builds upon the GMP capabl

Yahoo | November 10, 2022

SQZ Biotechnologies Reports Third Quarter 2022 Financial Results and Recent Portfolio Updates

WATERTOWN, Mass., November 09, 2022--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported third quarter 2022 financial results and recent portfolio updates.

Yahoo | November 9, 2022

Multiple insiders bought SQZ Biotechnologies Company (NYSE:SQZ) stock earlier this year, a positive sign for shareholders

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Yahoo | November 8, 2022

Analyst Bullish On SQZ Biotech's Technology For Solving Cell Therapy Challenges

HC Wainwright initiated coverage on SQZ Biotechnologies Company (NYSE: SQZ) with a Buy rating and a price target of $10. SQZ is focused on developing novel therapeutic cell therapy platforms centering around the company's Cell Squeeze technology. The analyst writes that there is significant potential for the Cell Squeeze technology for many disease areas and oncology indications. The likely next target in oncology is KRAS G12D and/or G12V mutations, given positive preclinical results which showe

Yahoo | October 20, 2022

Read More 'SQZ' Stories Here

SQZ Price Returns

1-mo -44.44%
3-mo N/A
6-mo -59.21%
1-year -86.38%
3-year N/A
5-year N/A
YTD -82.64%
2021 -69.19%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7055 seconds.